Suppr超能文献

腕管综合征单次皮质类固醇注射后复发症状的预后指标。

Prognostic Indicators for Recurrent Symptoms After a Single Corticosteroid Injection for Carpal Tunnel Syndrome.

机构信息

Department of Orthopaedic Surgery, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115. E-mail address for P.E. Blazar:

333 Harrison Street, Apartment #745, San Francisco, CA 94105. E-mail address:

出版信息

J Bone Joint Surg Am. 2015 Oct 7;97(19):1563-70. doi: 10.2106/JBJS.N.01162.

Abstract

BACKGROUND

Corticosteroid injections are commonly used in the treatment of carpal tunnel syndrome in adults. This study sought to determine success rates early on and at one year postoperatively of a single corticosteroid injection while identifying prognostic indicators for symptom recurrence and repeat intervention.

METHODS

Fifty-four consecutive wrists in forty-nine patients with carpal tunnel syndrome treated with a single corticosteroid injection were prospectively enrolled. Demographic data and information on comorbidities were identified with a study-specific questionnaire. The Boston Carpal Tunnel Questionnaire was administered prior to injection. Patients returned to clinic at six weeks and were contacted at three, six, nine, and twelve months post-injection to determine symptom and intervention status. Kaplan-Meier analysis and Cox regression modeling were used to estimate recurrence rates and to identify predictors of symptom recurrence and repeat intervention.

RESULTS

Fifty-four symptomatic wrists in forty-nine patients with a mean age of fifty-three years were included. Two patients (two wrists) were lost to follow-up. Patients reported symptom recurrence in thirty-one wrists at a median duration of 155 days post-injection. Nineteen wrists underwent carpal tunnel release at a median time of 181 days after the injection. No patient underwent a repeat injection. In our study, diabetic patients were at a 2.6-fold greater risk of reporting recurring symptoms within a one-year follow-up period. Survivorship free from symptom recurrence was 53% at six months and 31% at twelve months; survivorship from repeat intervention was 81% at six months and 66% at twelve months.

CONCLUSIONS

A single injection achieved symptom relief in 79% of patients at six weeks; these results were maintained in 31% of patients at twelve months. Diabetic patients were at higher risk of symptom recurrence.

摘要

背景

皮质类固醇注射在成人腕管综合征的治疗中很常用。本研究旨在确定单次皮质类固醇注射后早期和一年后的成功率,并确定症状复发和重复干预的预测指标。

方法

前瞻性纳入 49 例 54 只腕部接受单次皮质类固醇注射治疗的腕管综合征患者。采用专门的研究问卷确定人口统计学数据和合并症信息。在注射前进行波士顿腕管问卷评估。患者在 6 周时返回诊所,并在注射后 3、6、9 和 12 个月时联系,以确定症状和干预情况。采用 Kaplan-Meier 分析和 Cox 回归模型来估计复发率,并确定症状复发和重复干预的预测因素。

结果

纳入了 49 例平均年龄为 53 岁的 54 只症状腕部。2 例(2 只腕部)失访。患者在注射后中位 155 天报告了 31 只腕部的症状复发。19 只腕部在注射后中位 181 天接受了腕管松解术。没有患者接受重复注射。在我们的研究中,糖尿病患者在一年随访期内报告症状复发的风险增加了 2.6 倍。6 个月时无症状复发的生存率为 53%,12 个月时为 31%;6 个月时无重复干预的生存率为 81%,12 个月时为 66%。

结论

单次注射在 6 周时使 79%的患者症状缓解;这些结果在 12 个月时保持在 31%的患者中。糖尿病患者症状复发的风险更高。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验